Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC)

Grössmann N
Record ID 32017000424
English
Authors' recommendations: In conclusion, the treatment with abemaciclib offers a statistically significant improvement in PFS (+7.1 months) and ORR (+19.1%) with an inferior safety profile at high costs. Due to the immature OS data and the missing QoL results, there is a need for long-term data to avoid a systematic overestimation of the treatment effect of abemaciclib. In the future, the identification of a robust predictive biomarker to identify the most suitable patients will be crucial for the class of CDK4/6 inhibitors. Finally, direct comparisons of abemaciclib to palbociclib and ribociclib are essential to investigate which treatment option is most beneficial for HR-positive, HER2-negative ABC patients.
Details
Project Status: Completed
URL for project: http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published: 2017
URL for published report: http://eprints.hta.lbg.ac.at/1137/1/DSD_HSO_Nr.72.pdf
URL for additional information: http://eprints.hta.lbg.ac.at/1137/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Austria
MeSH Terms
  • Aminopyridines
  • Benzimidazoles
  • Breast
  • Breast Neoplasms
  • Estradiol
  • Humans
  • Fulvestrant
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.